WebPR Newswire. 01/09 08:54. OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024. PR Newswire. 12/29 16:48. --Stifel Downgrades Evofem Biosciences to Hold From Buy, Adjusts Price Target to $0.50 From $3. MT Newswires. WebJul 7, 2024 · Evofem's share trajectory has been a struggle in futility. During its short life as a public company it has engineered two reverse splits. The first was on 01/18/2024; it was a 1 for 6 reverse ...
EVFM - Evofem Biosciences Stock Interactive Chart - Barchart.com
WebShares Outstanding. Evofem Biosciences shares outstanding from 2013 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares. WebFeb 27, 2024 · -- Evofem now has four Orange Book listed patents covering Phexxi into 2033 -- SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that two additional U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. … smithville funeral home obituaries
Evofem Wins Phexxi Coverage with Largest Payer in New York …
WebApr 6, 2024 · 62,6%. More Financials. Company. Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. It is engaged in developing and commercializing … WebApr 12, 2024 · Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required PR Newswire SAN DIEGO, April 12, 2024 —... 12/04/2024 13:13:36 Cookie Policy +44 (0) 203 8794 460 Free Membership Login. Monitor; Quote; Charts; Trades; News; Financials; Toplists; Alerts; Portfolio; WebNov 15, 2024 · Evofem's ability to obtain the necessary regulatory approvals for its product candidates and the timing of such approvals, and, Any other risk factors detailed in … smithville flats ny zip